? Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in utero and continues through the period of breastfeeding, then starts again at the time of sexual debut and continues into adulthood. Prevention of HIV through adulthood will require an active vaccine that elicits persistent immunity. Yet, current HIV vaccine platforms have failed to induce highly- protective immunity in adults in preclinical and clinical studies. Excitingly, recent studies indicate that achieving durable, polyfunctional, and bnAb responses following HIV infection may be more easily achieved in infancy than in an adult immune system. Yet, gaps remain in our understanding of whether HIV vaccination in early life is advantageous for achievement of protective, long lasting HIV immunity. Because of its many similarities in development, physiology, immunology and pathogenesis, nonhuman primate (NHP) models of HIV infection are highly appropriate to explore these research questions. Thus, this HIVRAD Program will use the NHP model to test the hypothesis that HIV Env vaccine platforms administered in early life and boosted in pre- adolescence will achieve durable, polyfunctional, and mature immune responses that will be more efficacious at prevention of sexual transmission than immunization starting in preadolescence. In this renewal, the NHP Core will continue to support NHP studies in Project 1, ?Age-related impact on early life B cell lineage-designed SOSIP HIV Env vaccination? (P.I. Dr. S. Permar, Duke University) and Project 2, ?RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responses? (P.I. Dr. K. De Paris, UNC-CH). Projects test the same hypothesis using 2 different vaccine platforms, SOSIP and mRNA-LNP, respectively. The Nonhuman Primate Core (NHP Core) is an integral component of the overall HIVRAD Program and provides direct support to the Projects by coordinating and implementing all the NHP experiments (including regulatory approvals, and all procedures related to immunizations and sample collections), and by developing/testing a repeated low-dose rectal SHIV challenge model in adolescent macaques to test vaccine efficacy. This Core has a longstanding track-record of collaboration with the 2 Project Leads/Overall P.I?s, and will communicate frequently with both Projects and other Cores to assure all the experimental needs are met with due diligence. The NHP Core uses the unique resources and infrastructure of the California National Primate Research Center (CNPRC), out of which it operates, and the expertise of the Core Lead and staff. The CNPRC is built on a service-oriented and interdisciplinary mission of advancing non-human primate models of human diseases and translational research. Resources at CNPRC include a large rhesus macaque breeding colony, experience with time-mated pregnancies, nursery-rearing of infant macaques, and all other procedures of monitoring and sample collections that are essential to the successful completion of the Projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI117915-06
Application #
9893370
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Himes, Jonathon E; Goswami, Ria; Mangan, Riley J et al. (2018) Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. Mucosal Immunol 11:1716-1726
Dennis, Maria; Eudailey, Joshua; Pollara, Justin et al. (2018) Co-administration of CH31 broadly neutralizing antibody does not affect development of vaccine-induced anti-HIV-1 envelope antibody responses in infant Rhesus macaques. J Virol :
Eudailey, Joshua A; Dennis, Maria L; Parker, Morgan E et al. (2018) Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. mSphere 3:
Martinez, David R; Fouda, Genevieve G; Peng, Xinxia et al. (2018) Noncanonical placental Fc receptors: What is their role in modulating transplacental transfer of maternal IgG? PLoS Pathog 14:e1007161
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Phillips, Bonnie; Fouda, Genevieve G; Eudailey, Josh et al. (2017) Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Clin Vaccine Immunol 24:
Zhang, Ruijun; Martinez, David R; Nguyen, Quang N et al. (2016) Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. Nat Commun 7:12131
Nelson, Cody S; Pollara, Justin; Kunz, Erika L et al. (2016) Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. J Virol 90:4951-4965
Nguyen, Quang N; Himes, Jonathon E; Martinez, David R et al. (2016) The Impact of the Gut Microbiota on Humoral Immunity to Pathogens and Vaccination in Early Infancy. PLoS Pathog 12:e1005997
Kelly, Matthew S; Benjamin, Daniel K; Puopolo, Karen M et al. (2015) Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia. JAMA Pediatr 169:e153785

Showing the most recent 10 out of 11 publications